Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eight brokerages that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $11.13.
A number of research analysts have recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Sutro Biopharma in a research note on Monday, November 18th. Wedbush reissued an “outperform” rating and issued a $8.00 price objective on shares of Sutro Biopharma in a research note on Tuesday, December 10th. Wells Fargo & Company dropped their price objective on Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 11th. JMP Securities reissued a “market outperform” rating and issued a $17.00 price objective on shares of Sutro Biopharma in a research note on Wednesday, December 11th. Finally, Piper Sandler reissued an “overweight” rating and issued a $11.00 price objective on shares of Sutro Biopharma in a research note on Friday, October 11th.
Read Our Latest Research Report on STRO
Sutro Biopharma Price Performance
Institutional Trading of Sutro Biopharma
Hedge funds and other institutional investors have recently made changes to their positions in the business. Gladius Capital Management LP purchased a new stake in shares of Sutro Biopharma during the 3rd quarter valued at $28,000. ProShare Advisors LLC lifted its holdings in shares of Sutro Biopharma by 49.1% during the 2nd quarter. ProShare Advisors LLC now owns 16,316 shares of the company’s stock valued at $48,000 after purchasing an additional 5,373 shares during the last quarter. Virtu Financial LLC purchased a new position in Sutro Biopharma in the 3rd quarter worth $77,000. Intech Investment Management LLC purchased a new position in Sutro Biopharma in the 3rd quarter worth $91,000. Finally, The Manufacturers Life Insurance Company raised its stake in Sutro Biopharma by 27.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,943 shares of the company’s stock worth $97,000 after acquiring an additional 7,082 shares during the last quarter. Hedge funds and other institutional investors own 96.99% of the company’s stock.
Sutro Biopharma Company Profile
Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.
Recommended Stories
- Five stocks we like better than Sutro Biopharma
- Do ETFs Pay Dividends? What You Need to Know
- SAP’s Strong Momentum: A Bullish Setup for Investors
- Stock Average Calculator
- BlackRock Breaks Records: Why the Stock Still Has Room to Run
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Duke vs. NRG: Which Energy Stock Will Power Higher Gains?
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.